KR100215357B1 - 치환된-4-아미노-3-피리디놀, 이의 제조방법 및 이를 포함하는 약제학적 조성물 - Google Patents

치환된-4-아미노-3-피리디놀, 이의 제조방법 및 이를 포함하는 약제학적 조성물 Download PDF

Info

Publication number
KR100215357B1
KR100215357B1 KR1019910016850A KR910016850A KR100215357B1 KR 100215357 B1 KR100215357 B1 KR 100215357B1 KR 1019910016850 A KR1019910016850 A KR 1019910016850A KR 910016850 A KR910016850 A KR 910016850A KR 100215357 B1 KR100215357 B1 KR 100215357B1
Authority
KR
South Korea
Prior art keywords
formula
compound
lower alkyl
hydrogen
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1019910016850A
Other languages
English (en)
Korean (ko)
Other versions
KR920006318A (ko
Inventor
그레고리마이클셔츠케
케빈제임스캐플스
존딕크토머
니콜라스조셉리브
존게라드주르칵
Original Assignee
제이 티. 쉑 2세
훽스트-러셀 파마슈티칼즈 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 제이 티. 쉑 2세, 훽스트-러셀 파마슈티칼즈 인코포레이티드 filed Critical 제이 티. 쉑 2세
Publication of KR920006318A publication Critical patent/KR920006318A/ko
Application granted granted Critical
Publication of KR100215357B1 publication Critical patent/KR100215357B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/26—Radicals substituted by halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Surface Treatment Of Glass (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
KR1019910016850A 1990-09-27 1991-09-27 치환된-4-아미노-3-피리디놀, 이의 제조방법 및 이를 포함하는 약제학적 조성물 Expired - Fee Related KR100215357B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58911390A 1990-09-27 1990-09-27
US7/589,113 1990-09-27

Publications (2)

Publication Number Publication Date
KR920006318A KR920006318A (ko) 1992-04-27
KR100215357B1 true KR100215357B1 (ko) 1999-08-16

Family

ID=24356648

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019910016850A Expired - Fee Related KR100215357B1 (ko) 1990-09-27 1991-09-27 치환된-4-아미노-3-피리디놀, 이의 제조방법 및 이를 포함하는 약제학적 조성물

Country Status (22)

Country Link
US (3) US5821239A (enExample)
EP (1) EP0477903B1 (enExample)
JP (1) JP3090511B2 (enExample)
KR (1) KR100215357B1 (enExample)
AT (1) ATE136297T1 (enExample)
AU (1) AU637720B2 (enExample)
CA (1) CA2052433C (enExample)
CZ (1) CZ282002B6 (enExample)
DE (1) DE69118470T2 (enExample)
DK (1) DK0477903T3 (enExample)
ES (1) ES2085940T3 (enExample)
FI (1) FI914504A7 (enExample)
GR (1) GR3019742T3 (enExample)
HU (1) HUT60247A (enExample)
IE (1) IE73874B1 (enExample)
IL (1) IL99581A (enExample)
NO (1) NO913778L (enExample)
NZ (1) NZ239935A (enExample)
PT (1) PT99073B (enExample)
TW (1) TW200462B (enExample)
YU (1) YU158591A (enExample)
ZA (1) ZA917692B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6218383B1 (en) 1998-08-07 2001-04-17 Targacept, Inc. Pharmaceutical compositions for the prevention and treatment of central nervous system disorders
FR2813891B1 (fr) * 2000-09-14 2005-01-14 Immunotech Sa Reactif multifonctionnel pour erythrocytes mettant en jeu des carbamates et applications
DE10102791B4 (de) * 2001-01-22 2004-04-15 Ifm Electronic Gmbh Elektrischer Meßumformer
KR20040068240A (ko) * 2001-12-14 2004-07-30 노보 노르디스크 에이/에스 호르몬 민감성 리파아제의 활성을 감소시키기 위한 화합물및 그들의 사용
KR100443983B1 (ko) 2002-01-15 2004-08-09 삼성전자주식회사 냉장고
US8007826B2 (en) 2003-12-11 2011-08-30 Acorda Therapeutics, Inc. Sustained release aminopyridine composition
US8354437B2 (en) 2004-04-09 2013-01-15 Acorda Therapeutics, Inc. Method of using sustained release aminopyridine compositions
EP2607362B1 (en) * 2005-02-17 2014-12-31 Astellas Pharma Inc. Piperidine and piperazine carboxylates as FAAH inhibitors
BRPI0903914A2 (pt) * 2008-09-10 2015-07-21 Acorda Therapeutics Inc Uso de um composto, método para analisar a eficácia de uma composição de liberação prolongada, e, composição farmacêutica.
EP2533645B1 (en) 2010-02-09 2016-07-27 The Johns Hopkins University Methods and compositions for improving cognitive function
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
CN104853755B (zh) 2012-12-13 2017-08-22 H.隆德贝克有限公司 包含沃替西汀和多奈哌齐的组合物
EP2968237A4 (en) 2013-03-15 2016-08-31 Univ Johns Hopkins METHOD AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION
EP2968220B1 (en) 2013-03-15 2021-05-05 Agenebio, Inc. Methods and compositions for improving cognitive function
MX384391B (es) 2015-05-22 2025-03-14 Agenebio Inc Composiciones farmacéuticas de levetiracetam de liberación extendida.
JP6899120B2 (ja) * 2016-10-12 2021-07-07 株式会社ナノエッグ アセチルコリンエステラーゼ（ＡＣｈＥ）阻害剤

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179563A (en) * 1978-05-19 1979-12-18 Warner-Lambert Company 3-Aryloxy-substituted-aminopyridines and methods for their production
US4734275A (en) * 1983-08-19 1988-03-29 Research Corporation Anti-curare agents
DE3514073A1 (de) * 1985-04-18 1986-10-23 Hoechst Ag, 6230 Frankfurt Mehrfach substituierte pyridin-1-oxide, verfahren zu ihrer herstellung, die sie enthaltenden arzneimittel und ihre verwendung
US4735958A (en) * 1986-12-22 1988-04-05 Warner-Lambert Company Trans-6-[2-[2-(substituted-phenyl)-3- (or 4-) heteroaryl-5-substituted-1H-pyrrol-1-yl]-ethyl]tetrahydro-4-hydroxy-2H-pyran-2-one inhibitors of cholesterol biosynthesis
US4831044A (en) * 1987-10-29 1989-05-16 Ici Americas Inc. Fungicidal pyridyl cyclopropane carboxamidines
US4994473A (en) * 1987-11-17 1991-02-19 Ici Americas Inc. Pyridyl containing insecticides
US5019574A (en) * 1988-09-30 1991-05-28 Chugai Seiyaku Kabushiki Kaisha 3,4-diaminoquinoline and 3,4-diamino-5,6,7,8-tetrahydroquinoline compounds useful for improving psychoneural function
FI90417C (fi) * 1988-11-16 1994-02-10 Hoechst Marion Roussel Inc Menetelmä terapeuttisesti aktiivisten hydroksi-1,2,3,4-tetrahydroaminoakridiinien valmistamiseksi
US4931457B1 (en) * 1989-06-28 1993-11-16 Hoechst-Roussel Pharmaceuticals Incorporated Naphthylamino-and naphthyloxy-pyridineamin compounds useful as topical antiinflammatory agents for the treatment of skin disorders

Also Published As

Publication number Publication date
US5869480A (en) 1999-02-09
ES2085940T3 (es) 1996-06-16
HUT60247A (en) 1992-08-28
AU637720B2 (en) 1993-06-03
GR3019742T3 (en) 1996-07-31
FI914504A7 (fi) 1992-03-28
JPH04261157A (ja) 1992-09-17
EP0477903B1 (en) 1996-04-03
CA2052433A1 (en) 1992-03-28
TW200462B (enExample) 1993-02-21
PT99073B (pt) 1999-02-26
IL99581A0 (en) 1992-08-18
US5821239A (en) 1998-10-13
CS293691A3 (en) 1992-04-15
FI914504A0 (fi) 1991-09-25
EP0477903A3 (en) 1992-08-05
YU158591A (sh) 1994-12-28
NO913778D0 (no) 1991-09-26
HU913075D0 (en) 1992-01-28
ATE136297T1 (de) 1996-04-15
DE69118470D1 (de) 1996-05-09
PT99073A (pt) 1992-08-31
NO913778L (no) 1992-03-30
DK0477903T3 (da) 1996-07-29
IE73874B1 (en) 1997-07-02
JP3090511B2 (ja) 2000-09-25
DE69118470T2 (de) 1996-09-19
CZ282002B6 (cs) 1997-04-16
NZ239935A (en) 1995-07-26
IL99581A (en) 1995-07-31
KR920006318A (ko) 1992-04-27
IE913389A1 (en) 1992-04-08
EP0477903A2 (en) 1992-04-01
US5866565A (en) 1999-02-02
ZA917692B (en) 1992-05-27
AU8475691A (en) 1992-04-02
CA2052433C (en) 2003-04-15

Similar Documents

Publication Publication Date Title
KR100215357B1 (ko) 치환된-4-아미노-3-피리디놀, 이의 제조방법 및 이를 포함하는 약제학적 조성물
KR890002104B1 (ko) 4-치환된-2-아제티디논 화합물의 제조방법
US5885985A (en) Guanidine derivatives useful in therapy
US4933368A (en) N-phenylbenzamide derivatives
NO177535C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive peptidforbindelser
US3365458A (en) N-aryl-n'-cyclopropyl-ethylene diamine derivatives
KR870003130A (ko) 테이코플라닌 화합물의 아미드
ES2257328T3 (es) Diazepanes sustituidos.
US3345379A (en) 7-imidomethyl-6-demethyl-6-deoxytetracyclines
ES8700856A1 (es) Un procedimiento para la preparacion de compuestos de 1, 4-dihidropiridina
FI892637A0 (fi) Menetelmä valmistaa farmakologisesti arvokasta kefeemiyhdistettä
FI57933B (fi) Foerfarande foer framstaellning av terapeutiskt aktiva olefina arylketoner
US4032559A (en) N,2-dicyanoacetimidates
US4150146A (en) Process for the preparation of unsymmetrically 1,3-disubstituted nitroso ureas
Takeuchi et al. Synthesis and antitumor activity of fused quinoline derivatives. IV. Novel 11-aminoindolo [3, 2-b] quinolines
GB962293A (en) New sydnonimines and process for their manufacture
JPS59108794A (ja) 新規トリシクロフォスファザン誘導体、その製造方法及び該誘導体を含む抗腫瘍剤
EP0302874B1 (en) Indoloquinone compounds
Zakharkin et al. Some reactions of 3-amino-o-carboranes
US3058986A (en) N-ammoalkyl-x-phenyl-x-lower alkyl-z-
US3068235A (en) Quaternary ammonium salts of omega-(n-methyl-2,6-dimethylanilino) alkyl halides
KR101849775B1 (ko) N-아로일우레아 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 암 예방 및 치료용 조성물
EP1326844A2 (en) Process for preparation of n-substituted 2-sulfanylimidazoles
US3441594A (en) Substituted hydrazine compounds
EP1027041A1 (en) Novel cyanoaziridines for treating cancer

Legal Events

Date Code Title Description
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20030519

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20040525

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20040525